{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:33:39Z","timestamp":1771554819897,"version":"3.50.1"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Treatment of <jats:italic>Mycobacterium abscessus<\/jats:italic> (MAB) infections is complicated by the lack of bactericidal antibiotics, the ability of MAB to persist in the hypoxic environment of granulomas and the intrinsic antibiotic resistance, which results in patient treatment with drug combinations for several months. Therefore, the search for new drugs\/drug combinations is an urgent need. This review provides a comprehensive update on the activity in the lungs of MAB-infected mice of new and old bactericidal and bacteriostatic compounds, alone and in combination, which showed killing greater than or equal to clinically used antibiotics and combination components. The acute model (4\u201314 days of treatment) was preferred in most single-drug efficacy testing procedures while the chronic model (28\u201342 days) was primarily used for combinations. Overall, 15 of 17 new compounds and 13 of 14 combinations decreased MAB colony forming units (CFUs) more than comparator drugs or combination components. The most potent combinations were those formed by bactericidal agents (\u22651\u2212log<jats:sub>10<\/jats:sub> CFU reduction compared to the initial bacterial burden), consisting of two \u03b2-lactams and a \u03b2-lactam plus a \u03b2-lactamase inhibitor. Among the other combinations, activity of the bactericidal compounds was usually slightly increased by the bacteriostatic agents that, however, preserved the bactericidal core of combinations and suppressed emergence of drug resistance. Overall, these data suggest that there is an urgent need for systematic <jats:italic>in vivo<\/jats:italic> investigations on anti-MAB activity of combinations containing bactericidal drugs that are part of current treatment guidelines or of new, preferably oral compounds, to ultimately eradicate non-replicating persisters at the sites of disease.<\/jats:p>","DOI":"10.3389\/fmicb.2025.1616149","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:33:50Z","timestamp":1754026430000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Activity of combinations of bactericidal and bacteriostatic compounds in Mycobacterium abscessus-infected mice: an overview"],"prefix":"10.3389","volume":"16","author":[{"given":"Alessio","family":"Lanni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Iona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanfranco","family":"Fattorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Giannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Iacobino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1092317","DOI":"10.3389\/fcimb.2023.1092317","article-title":"Metabolic pathways that permit Mycobacterium avium subsp. hominissuis to transition to different environments encountered within the host during infection.","volume":"13","author":"Abukhalid","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"ofad312","DOI":"10.1093\/ofid\/ofad312","article-title":"Eradicating pulmonary Mycobacterium abscessus: The promise of dual \u03b2-Lactam therapy.","volume":"10","author":"Alahmdi","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/path.2185","article-title":"Interferon-gamma-dependent mechanisms of mycobacteria-induced pulmonary immunopathology: The role of angiostasis and CXCR3-targeted chemokines for granuloma necrosis.","volume":"212","author":"Aly","year":"2007","journal-title":"J. Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0140021","DOI":"10.1128\/AAC.01400-21","article-title":"Cyclohexyl-griselimycin is active against Mycobacterium abscessus in mice.","volume":"66","author":"Aragaw","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e00272-17","DOI":"10.1128\/mBio.00272-17","article-title":"Targeting energy metabolism in Mycobacterium tuberculosis, a new paradigm in antimycobacterial drug discovery.","volume":"8","author":"Bald","year":"2017","journal-title":"mBio"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0031924","DOI":"10.1128\/aac.00319-24","article-title":"Dual \u03b2-lactam for treatment of pulmonary Mycobacterium abscessus in a child.","volume":"68","author":"Becken","year":"2024","journal-title":"Antimicrob Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"eabj3860","DOI":"10.1126\/scitranslmed.abj3860","article-title":"Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in Mycobacterium abscessus.","volume":"14","author":"Belardinelli","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e8614","DOI":"10.1371\/journal.pone.0008614","article-title":"Unique flexibility in energy metabolism allows mycobacteria to combat starvation and hypoxia.","volume":"5","author":"Berney","year":"2010","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fcimb.2017.00100","article-title":"The diverse cellular and animal models to decipher the physiopathological traits of Mycobacterium abscessus infection.","volume":"7","author":"Bernut","year":"2017","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.3389\/fmicb.2018.02417","article-title":"Novel screen to assess bactericidal activity of compounds against non-replicating Mycobacterium abscessus.","volume":"9","author":"Berube","year":"2018","journal-title":"Front. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e00834-19","DOI":"10.1128\/JCM.00834-19","article-title":"Antimycobacterial susceptibility testing of nontuberculous mycobacteria.","volume":"57","author":"Brown-Elliott","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.antiviral.2018.10.007","article-title":"The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K\/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy.","volume":"160","author":"Chan","year":"2018","journal-title":"Antiviral Res."},{"key":"B13","year":"2018","journal-title":"Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/futurepharmacol3030041","article-title":"Moles of molecules against Mycobacterium abscessus: A review of current research.","volume":"3","author":"Cocorullo","year":"2023","journal-title":"Fut. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ijpharm.2016.01.004","article-title":"Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.","volume":"499","author":"Collier","year":"2016","journal-title":"Int. J. Pharm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jac\/dkae046","article-title":"Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection.","volume":"79","author":"Cotroneo","year":"2024","journal-title":"J. Antimicrob Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"10360","DOI":"10.1038\/s41467-024-54666-4","article-title":"Use of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection.","volume":"15","author":"Cristinziano","year":"2024","journal-title":"Nat. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline.","volume":"56","author":"Daley","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102503","DOI":"10.1016\/j.tube.2024.102503","article-title":"Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.","volume":"147","author":"Dartois","year":"2024","journal-title":"Tuberculosis (Edinb)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41573-024-00897-5","article-title":"Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.","volume":"23","author":"Dartois","year":"","journal-title":"Nat. Rev. Drug Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0008023","DOI":"10.1128\/cmr.00080-23","article-title":"Toward better cures for Mycobacterium abscessus lung disease.","volume":"37","author":"Dartois","year":"","journal-title":"Clin. Microbiol. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"11315","DOI":"10.1038\/s41598-024-61901-x","article-title":"Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.","volume":"14","author":"Dash","year":"2024","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1574-6968.1998.tb13040.x","article-title":"Oxygen depletion induced dormancy in Mycobacterium smegmatis.","volume":"163","author":"Dick","year":"1998","journal-title":"FEMS Microbiol. Lett."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0352921","DOI":"10.1128\/mbio.03529-21","article-title":"Inhibiting Mycobacterium abscessus cell wall synthesis: Using a novel diazabicyclooctane \u03b2-Lactamase inhibitor to augment \u03b2-Lactam action.","volume":"66","author":"Dousa","year":"2022","journal-title":"mBio"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0060924","DOI":"10.1128\/mbio.00609-24","article-title":"Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus.","volume":"15","author":"Dousa","year":"2024","journal-title":"mBio"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1099\/mic.0.000325","article-title":"Metabolite analysis of Mycobacterium species under aerobic and hypoxic conditions reveals common metabolic traits.","volume":"162","author":"Drapal","year":"2016","journal-title":"Microbiology (Reading)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41579-019-0273-7","article-title":"The mycobacterial cell envelope - a moving target.","volume":"18","author":"Dulberger","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e01225-17","DOI":"10.1128\/AAC.01225-17","article-title":"Bedaquiline Inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish.","volume":"61","author":"Dupont","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1002\/med.21798","article-title":"Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.","volume":"41","author":"Egorova","year":"2021","journal-title":"Med. Res. Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1164\/rccm.201508-1586IM","article-title":"Biofilm formation by Mycobacterium abscessus in a lung cavity.","volume":"193","author":"Fennelly","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1016\/j.bmc.2017.05.015","article-title":"Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity.","volume":"25","author":"Franz","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0052823","DOI":"10.1128\/aac.00528-23","article-title":"The in vitro effect of new combinations of carbapenem-\u03b2-lactamase inhibitors for Mycobacterium abscessus.","volume":"67","author":"Fr\u00f6berg","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0151421","DOI":"10.1128\/AAC.01514-21","article-title":"A Mycobacterium tuberculosis NBTI DNA gyrase inhibitor is active against Mycobacterium abscessus.","volume":"65","author":"Ganapathy","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e02420-20","DOI":"10.1128\/AAC.02420-20","article-title":"A Leucyl-tRNA synthetase inhibitor with broad-spectrum anti-mycobacterial activity.","volume":"95","author":"Ganapathy","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.3390\/molecules27206948","article-title":"Why matter matters: Fast-tracking Mycobacterium abscessus drug discovery.","volume":"27","author":"Ganapathy","year":"2022","journal-title":"Molecules"},{"key":"B36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13065-018-0441-2","article-title":"Decaprenyl-phosphoryl-ribose 2\u2019-epimerase (DprE1): Challenging target for antitubercular drug discovery.","volume":"12","author":"Gawad","year":"2018","journal-title":"Chem. Cent. J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4415\/ANN_23_02_06","article-title":"Epidemiology and drug susceptibility of nontuberculous mycobacteria (NTM) in Italy in 2016-2020.","volume":"59","author":"Giannoni","year":"2023","journal-title":"Ann. Ist. Super Sanita"},{"key":"B38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease.","volume":"161","author":"Griffith","year":"2022","journal-title":"Chest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2125.2011.03991.x","article-title":"Neurotoxic effects associated with antibiotic use: Management considerations.","volume":"72","author":"Grill","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British thoracic society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"B41","doi-asserted-by":"publisher","first-page":"104461","DOI":"10.1016\/j.ebiom.2023.104461","article-title":"A broad-spectrum synthetic antibiotic that does not evoke bacterial resistance.","volume":"89","author":"Heithoff","year":"2023","journal-title":"EBioMedicine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"102295","DOI":"10.1016\/j.tube.2022.102295","article-title":"Mab2780c, a TetV-like efflux pump, confers high-level spectinomycin resistance in Mycobacterium abscessus.","volume":"138","author":"Hurst-Hess","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0038124","DOI":"10.1128\/msphere.00381-24","article-title":"Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung disease.","volume":"9","author":"Ignatius","year":"2024","journal-title":"mSphere"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jiph.2022.08.016","article-title":"An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis.","volume":"15","author":"Imran","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"B45","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus.","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40121-022-00750-5","article-title":"Contemporary pharmacotherapies for nontuberculosis mycobacterial infections: A narrative review.","volume":"12","author":"Johnson","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0221221","DOI":"10.1128\/aac.02212-21","article-title":"A rabbit model to study antibiotic penetration at the site of infection for nontuberculous mycobacterial lung disease: Macrolide case study.","volume":"66","author":"Kaya","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0174240","DOI":"10.1371\/journal.pone.0174240","article-title":"Comparison of chest CT findings in nontuberculous mycobacterial diseases vs. Mycobacterium tuberculosis lung disease in HIV-negative patients with cavities.","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0168421","DOI":"10.1128\/AAC.01684-21","article-title":"Early bactericidal activity of delpazolid (LCB01-0371) in patients with pulmonary tuberculosis.","volume":"66","author":"Kim","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e02752-16","DOI":"10.1128\/AAC.02752-16","article-title":"Activity of LCB01-0371, a novel oxazolidinone, against Mycobacterium abscessus.","volume":"61","author":"Kim","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"725","DOI":"10.5588\/ijtld.13.0871","article-title":"Comparable characteristics of tuberculous and non-tuberculous mycobacterial cavitary lung diseases.","volume":"18","author":"Kim","year":"2014","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1126\/science.aaa4690","article-title":"Targeting DnaN for tuberculosis therapy using novel griselimycins.","volume":"348","author":"Kling","year":"2015","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.2147\/IDR.S196874","article-title":"Enhancing the antibacterial activity of polymyxins using a nonantibiotic drug.","volume":"12","author":"Krishnamurthy","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3390\/microorganisms10071421","article-title":"Activity of drug combinations against Mycobacterium abscessus grown in aerobic and hypoxic conditions.","volume":"10","author":"Lanni","year":"2022","journal-title":"Microorganisms"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3390\/microorganisms11061511","article-title":"Eradication of drug-tolerant Mycobacterium tuberculosis 2022: Where we stand.","volume":"11","author":"Lanni","year":"2023","journal-title":"Microorganisms"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e00114-20","DOI":"10.1128\/AAC.00114-20","article-title":"Efficacy of bedaquiline, alone or in combination with imipenem, against Mycobacterium abscessus in C3HeB\/FeJ mice.","volume":"64","author":"Le Moigne","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijmyco.2014.11.066","article-title":"Microaerobic growth and anaerobic survival of Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium scrofulaceum.","volume":"4","author":"Lewis","year":"2015","journal-title":"Int. J. Mycobacteriol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0156223","DOI":"10.1128\/aac.01562-23","article-title":"Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.","volume":"68","author":"Li","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0058524","DOI":"10.1128\/aac.00585-24","article-title":"Case commentary: Dual \u03b2-lactam as part of regimen to treat Mycobacterium abscessus lung disease.","volume":"68","author":"Lippincott","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0066922","DOI":"10.1128\/aac.00669-22","article-title":"Activity of tricyclic pyrrolopyrimidine gyrase b inhibitor against Mycobacterium abscessus.","volume":"66","author":"Madani","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1038\/s41598-020-60452-1","article-title":"A mouse model of pulmonary Mycobacteroides abscessus infection.","volume":"10","author":"Maggioncalda","year":"2020","journal-title":"Sci. Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones.","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.3390\/app10072269","article-title":"Development of macozinone for TB treatment: An update.","volume":"7","author":"Makarov","year":"2020","journal-title":"Appl. Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0154521","DOI":"10.1128\/AAC.01545-21","article-title":"In vitro activity of bedaquiline and imipenem against actively growing, nutrient-starved, and intracellular Mycobacterium abscessus.","volume":"65","author":"Martins","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e0132723","DOI":"10.1128\/aac.01327-23","article-title":"Nitric oxide-releasing prodrug for the treatment of complex Mycobacterium abscessus infections.","volume":"68","author":"McDonald","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"6793","DOI":"10.3390\/ijms21186793","article-title":"Alternative and experimental therapies of Mycobacterium abscessus infections.","volume":"21","author":"Meir","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12864-016-2868-y","article-title":"Functional characterization of the Mycobacterium abscessus genome coupled with condition specific transcriptomics reveals conserved molecular strategies for host adaptation and persistence.","volume":"17","author":"Miranda-CasoLuengo","year":"2016","journal-title":"BMC Genom."},{"key":"B68","doi-asserted-by":"publisher","first-page":"106669","DOI":"10.1016\/j.ijantimicag.2022","article-title":"In vitro effects of diazabicyclooctane \u03b2-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex.","volume":"60","author":"Misawa","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B69","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.resinv.2019.12.006","article-title":"Comparison of the chest computed tomography findings between patients with pulmonary tuberculosis and those with Mycobacterium avium complex lung disease.","volume":"58","author":"Miura","year":"2020","journal-title":"Respir. Investig."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e40993","DOI":"10.7759\/cureus.40993","article-title":"A 40-Year-Old female with Mycobacterium abscessus successfully treated with a dual beta-lactam combination.","volume":"15","author":"Moguillansky","year":"2023","journal-title":"Cureus"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e0145922","DOI":"10.1128\/aac.01459-22","article-title":"Activity of oral tebipenem-avibactam in a mouse model of Mycobacterium abscessus lung infection.","volume":"67","author":"Negatu","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0079022","DOI":"10.1128\/aac.00790-22","article-title":"Strongly bactericidal all-oral \u03b2-Lactam combinations for the treatment of Mycobacterium abscessus lung disease.","volume":"66","author":"Negatu","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1331508","DOI":"10.3389\/fmicb.2024.1331508","article-title":"Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches.","volume":"15","author":"Nguyen","year":"2024","journal-title":"Front. Microbiol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"102301","DOI":"10.1016\/j.tube.2022.102301","article-title":"Preclinical murine models to study lung infection with Mycobacterium abscessus complex.","volume":"138","author":"Nicola","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1378\/chest.11-0425","article-title":"Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease.","volume":"141","author":"O\u2019Connell","year":"2012","journal-title":"Chest"},{"key":"B76","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12931-020-1273-x","article-title":"Characteristic chest CT findings for progressive cavities in Mycobacterium avium complex pulmonary disease: A retrospective cohort study.","volume":"21","author":"Oshitani","year":"2020","journal-title":"Respir. Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e02245-18","DOI":"10.1128\/AAC.02245-18","article-title":"Indole-2-Carboxamides are active against Mycobacterium abscessus in a mouse model of acute infection.","volume":"63","author":"Pandya","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e1011318","DOI":"10.1371\/journal.ppat.1011318","article-title":"The cell envelope of Mycobacterium abscessus and its role in pathogenesis.","volume":"19","author":"Parmar","year":"2023","journal-title":"PLoS Pathog"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e2314101120","DOI":"10.1073\/pnas.2314101120","article-title":"Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus.","volume":"121","author":"Phelps","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B80","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.cmi.2024.03.019","article-title":"Dual \u03b2-lactam therapy to improve treatment outcome in Mycobacterium abscessus disease.","volume":"30","author":"Pozuelo Torres","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"B81","doi-asserted-by":"publisher","first-page":"724725","DOI":"10.3389\/fphar.2021.724725","article-title":"Current molecular therapeutic agents and drug candidates for Mycobacterium abscessus.","volume":"12","author":"Quang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/pathogens9080641","article-title":"Preclinical models of nontuberculous mycobacteria infection for early drug discovery and vaccine research.","volume":"9","author":"Rampacci","year":"2020","journal-title":"Pathogens"},{"key":"B83","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of non-tuberculosis mycobacterial lung disease.","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e0064824","DOI":"10.1128\/aac.00648-24","article-title":"Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection.","volume":"68","author":"Rimal","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B85","doi-asserted-by":"publisher","first-page":"102482","DOI":"10.1016\/j.tube.2024.102482","article-title":"Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease.","volume":"146","author":"Rimal","year":"","journal-title":"Tuberculosis (Edinb)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e0066522","DOI":"10.1128\/msphere.00665-22","article-title":"Efficacy of omadacycline-containing regimen in a mouse model of pulmonary Mycobacteroides abscessus disease.","volume":"8","author":"Rimal","year":"2023","journal-title":"mSphere"},{"key":"B87","author":"Sakoulas","year":"2025","journal-title":"Durlobactam may be active in treating Mycobacterium abscessus."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e02404-19","DOI":"10.1128\/AAC.02404-19","article-title":"TBAJ-876, a 3,5-Dialkoxypyridine analogue of bedaquiline, is active against Mycobacterium abscessus.","volume":"64","author":"Sarathy","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e01540-19","DOI":"10.1128\/AAC.01540-19","article-title":"TBAJ-876 displays bedaquiline-like mycobactericidal potency without retaining the parental drug\u2019s uncoupler activity.","volume":"64","author":"Sarathy","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1021\/acsinfecdis.4c00948","article-title":"Toward a bactericidal oral drug combination for the treatment of Mycobacterium abscessus lung disease.","volume":"11","author":"Sarathy","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"6202","DOI":"10.3390\/ijms21176202","article-title":"MmpL3 inhibition: A new approach to treat nontuberculous mycobacterial infections.","volume":"21","author":"Sethiya","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e0117424","DOI":"10.1128\/aac.01174-24","article-title":"Durlobactam in combination with \u03b2-lactams to combat Mycobacterium abscessus.","volume":"69","author":"Shin","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1144210","DOI":"10.3389\/fcimb.2023.1144210","article-title":"Mycobacterium abscessus DosRS two-component system controls a species-specific regulon required for adaptation to hypoxia.","volume":"13","author":"Simcox","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.3390\/ijms24032951","article-title":"Design, synthesis and antimicrobial evaluation of new N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)(hetero)aryl-2-carboxamides as potential inhibitors of mycobacterial Leucyl-tRNA synthetase.","volume":"24","author":"\u0160lechta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"102268","DOI":"10.1016\/j.tube.2022.102268","article-title":"Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.","volume":"137","author":"Sriram","year":"2022","journal-title":"Tuberculosis (Edinb)"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1021\/acsinfecdis.0c00025","article-title":"Advancement of GyrB inhibitors for treatment of infections caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.","volume":"6","author":"Stokes","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e02613-18","DOI":"10.1128\/AAC.02613-18","article-title":"Select \u03b2-Lactam combinations exhibit synergy against Mycobacterium abscessus in vitro.","volume":"63","author":"Story-Roller","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e00614-19","DOI":"10.1128\/AAC.00614-19","article-title":"Synergistic efficacy of \u03b2-Lactam combinations against Mycobacterium abscessus pulmonary infection in mice.","volume":"63","author":"Story-Roller","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e1009965","DOI":"10.1371\/journal.ppat.1009965","article-title":"Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline.","volume":"17","author":"Sullivan","year":"2021","journal-title":"PLoS Pathog"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.3389\/fmicb.2018.02901","article-title":"Host variability in NTM disease: Implications for research needs.","volume":"9","author":"Swenson","year":"2018","journal-title":"Front. Microbiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"41775","DOI":"10.1038\/srep41775","article-title":"Effects of nutritional and ambient oxygen condition on biofilm formation in Mycobacterium avium subsp. hominissuis via altered glycolipid expression.","volume":"7","author":"Totani","year":"2017","journal-title":"Sci. Rep."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e65112","DOI":"10.7759\/cureus.65112","article-title":"Combination of imipenem-cilastatin-relebactam and amoxicillin in the antibiotic regimen in two cases of Mycobacterium abscessus lung infection.","volume":"16","author":"Vogiatzoglou","year":"2024","journal-title":"Cureus"},{"key":"B103","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.3390\/ijms22126346","article-title":"Activity of oritavancin and its synergy with other antibiotics against Mycobacterium abscessus infection in vitro and in vivo.","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/14787210.2023.2270158","article-title":"Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720.","volume":"21","author":"Winthrop","year":"2023","journal-title":"Exp. Rev. Anti. Infect. Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.drudis.2018.04.001","article-title":"NTM drug discovery: Status, gaps and the way forward.","volume":"23","author":"Wu","year":"2018","journal-title":"Drug Discov. Today"},{"key":"B106","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fmicb.2016.00947","article-title":"Mild nutrient starvation triggers the development of a small-cell survival morphotype in mycobacteria.","volume":"7","author":"Wu","year":"2016","journal-title":"Front. Microbiol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e0060122","DOI":"10.1128\/aac.00601-22","article-title":"A novel leucyl-trna synthetase inhibitor, MRX-6038, expresses anti-Mycobacterium abscessus activity in vitro and in vivo.","volume":"66","author":"Wu","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e0038123","DOI":"10.1128\/aac.00381-23","article-title":"ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant M. abscessus in caseum surrogate.","volume":"67","author":"Xie","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B109","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fmicb.2020.00359","article-title":"Extreme drug tolerance of Mycobacterium abscessus \u201cpersisters\u201d.","volume":"11","author":"Yam","year":"2020","journal-title":"Front. Microbiol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-2466-14-65","article-title":"Comparative chest computed tomography findings of non-tuberculous mycobacterial lung diseases and pulmonary tuberculosis in patients with acid fast bacilli smear-positive sputum.","volume":"14","author":"Yuan","year":"2014","journal-title":"BMC Pulm Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: Mechanism of action.","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B112","doi-asserted-by":"publisher","first-page":"eadi7558","DOI":"10.1126\/scitranslmed.adi7558","article-title":"An anti-mycobacterial conjugated oligoelectrolyte effective against Mycobacterium abscessus.","volume":"16","author":"Zhang","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e00236-20","DOI":"10.1128\/AAC.00236-20","article-title":"AR-12 exhibits direct and host-targeted antibacterial activity toward Mycobacterium abscessus.","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1115530","DOI":"10.3389\/fcimb.2023.1115530","article-title":"Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB\/c mice models.","volume":"13","author":"Zheng","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e0051823","DOI":"10.1128\/msphere.00518-23","article-title":"Sudapyridine (WX-081) antibacterial activity against Mycobacterium avium, Mycobacterium abscessus, and Mycobacterium chelonae in vitro and in vivo.","volume":"9","author":"Zheng","year":"2024","journal-title":"mSphere"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1616149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:33:51Z","timestamp":1754026431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1616149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":115,"alternative-id":["10.3389\/fmicb.2025.1616149"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1616149","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"1616149"}}